Reconsidering Urate-Lowering Therapy in Chronic Kidney Disease- Guideline Driven Perspectives on the Management of Asymptomatic Hyperuricaemia.

Authors

Sourabh Sharma, Sabine Karam, Intissar Haddiya, Sanjay Kalra

Published in

JPMA. The Journal of the Pakistan Medical Association. Volume 76. Issue 6. Pages 971-974.

Abstract

Hyperuricaemia is highly prevalent in patients with chronic kidney disease (CKD), primarily due to reduced renal urate excretion. Elevated serum uric acid (SUA) levels have been linked with CKD progression, cardiovascular disease, and mortality. However, association does not imply causation. Over the last decade, multiple studies have failed to demonstrate a renoprotective or cardiovascular benefit of urate-lowering therapy (ULT) in patients with asymptomatic hyperuricaemia. Consequently, major international societies, including Kidney Disease: Improving Global Outcomes (KDIGO), the American College of Rheumatology (ACR), and the European Alliance of Associations for Rheumatology (EULAR), recommend against pharmacologic treatment of asymptomatic hyperuricaemia, including in patients with CKD. This review synthesizes current guideline recommendations, randomized clinical trial evidence, and practical clinical considerations to delineate scenarios in which ULT should not be initiated in patients with chronic kidney disease, while highlighting the importance of supportive and nonpharmacologic management strategies.

PMID:
42363348
Bibliographic data and abstract were imported from PubMed on 27 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.